TOP > 外国特許検索 > ANTI-ATHEROSCLEROTIC AGENT AND SYMPTOM IDENTIFICATION METHOD FOR ARTERIOSCLEROSIS

ANTI-ATHEROSCLEROTIC AGENT AND SYMPTOM IDENTIFICATION METHOD FOR ARTERIOSCLEROSIS 新技術説明会

外国特許コード F180009460
整理番号 (S2017-0054-N0)
掲載日 2018年7月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP037624
国際公開番号 WO 2018074497
国際出願日 平成29年10月18日(2017.10.18)
国際公開日 平成30年4月26日(2018.4.26)
優先権データ
  • 特願2016-204783 (2016.10.19) JP
発明の名称 (英語) ANTI-ATHEROSCLEROTIC AGENT AND SYMPTOM IDENTIFICATION METHOD FOR ARTERIOSCLEROSIS 新技術説明会
発明の概要(英語) Disclosed is a novel means making it possible to suppress the formation of atherosclerotic lesions and treat arteriosclerosis. The anti-atherosclerotic agent according to the present invention comprises, as an active ingredient, a substance for selectively suppressing B2 cells. The substance for selectively suppressing B2 cells is for example an anti-CD23 antibody. A first embodiment of a method for assisting the identification of arteriosclerosis symptoms of the present application comprises using a sample isolated from a subject to measure the expression of at least one gene selected from a specific gene group. A second embodiment of the method comprises measuring the IgG3 level or total IgG level in a serum sample isolated from a subject.
従来技術、競合技術の概要(英語) BACKGROUND ART
Arteriosclerosis is a lifestyle-related disease in a final image. Diabetes, hypertension, dyslipidemia, chronic kidney disease, risk factors such as smoking (non-patent document 1) can be controlled, to control the accuracy of the onset of the present invention, such as catastrophe of the acute disease (myocardial infarction, cerebral infarction, the severity of the lower limb ischemia) is exhibited, the medical resource (fire emergency system, acute vessel-treated can be acute hospital personnel and equipment to a) maximize the use of the, in addition to the method of the regulator is not a rescue. Risk control strategy, the reliability is poor, also in clinical trials, and test subject population, with the risk relative to the effectiveness of the only.
The genesis of the present invention, the high-risk state as well as lifestyle-related diseases, inflammation, immune responses are considered to be derived from the disease. The inventors of the present invention, so far, such as serum molecule IL-5 autoantibodies involved in atherosclerosis has been reported (Non-Patent Document 2, Patent Document 1). However, readout of the arteriosclerosis genesis aggressive treatment means has not been developed yet.
Is Patent Document 2, an anti-CD20 antibody and B by the depleted treating atherosclerotic prevention that the invention is not disclosed. CD20 Is, peripheral blood or lymphoid organs 90% of the cell B of the surface of greater than 35kDa of the non-glycosylated phosphoprotein found and, between the occurrence of an initial pre-B cell expression, differentiation of transformed cells (Patent Document 2) to last. That is, when the anti-CD20 antibody, the target and the B cells generally, it is possible to reduce the number of the cells are assumed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • YOKOHAMA CITY UNIVERSITY
  • 発明者(英語)
  • ISHIGAMI, Tomoaki
  • CHEN, Lin
国際特許分類(IPC)
※ ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close